Claim OwnershipResearch To Practice | Oncology Videos
Subscribed: 594Played: 40,521
Subscribe
Copyright © 2023 Research To Practice. All Rights Reserved.
Description
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.
835 Episodes
Reverse
Featuring an interview with Dr Hanny Al-Samkari, including the following topics: VAYHIT1: A multicenter randomized, double-blind, Phase III trial evaluating ianalumab versus placebo in addition to first-line corticosteroids for patients with primary immune thrombocytopenia (ITP) (0:00) Secondary analysis results from VAYHIT3, a Phase II study of ianalumab for patients with primary ITP previously treated with at least 2 lines of therapy (8:15) Improved health-related quality of life and bleeding scores with the oral Bruton tyrosine kinase inhibitor rilzabrutinib in the open-label period of the multicenter Phase III LUNA 3 study for adults with ITP (12:23) Romiplostim for chemotherapy-induced thrombocytopenia in patients with colorectal, gastroesophageal and pancreatic cancer: A global Phase III randomized, placebo-controlled trial (16:01) CME information and select publications
Featuring perspectives from Prof Nicoletta Colombo and Dr Kathleen N Moore, including the following topics: Introduction (0:00) Promising Novel Agents and Strategies Under Investigation in Ovarian Cancer (2:35) Current Management of Newly Diagnosed and Relapsed/Refractory Ovarian Cancer(41:48) CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Ovarian Cancer | Faculty Presentation 2: Promising Novel Agents and Strategies Under Investigation in Ovarian Cancer — Nicoletta Colombo, MD CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Ovarian Cancer | Faculty Presentation 1: Current Management of Newly Diagnosed and Relapsed/Refractory Ovarian Cancer — Angeles Alvarez Secord, MD, MHSc CME information and select publications
Featuring an interview with Dr Christopher Lieu, including the following topics: Historical approach to the adjuvant treatment of localized colorectal cancer (CRC) (0:00) Perspectives on earlier-onset colorectal cancer and potential drivers; management of oligometastatic disease (13:16) Overview of cell-free DNA (circulating tumor DNA [ctDNA]) and techniques for its measurement (17:03) Reliability and prognostic capability of ctDNA as a biomarker for clinical status in patients with localized colorectal cancer (21:10) ctDNA assessment and treatment decision-making for patients with Stage II colon cancer (26:38) Potential incorporation of ctDNA assays into the management of metastatic colorectal cancer or microsatellite instability-high disease (34:29) Available clinical data with ctDNA assessment in localized rectal cancer (38:54) Current practice patterns with ctDNA assays for patients with localized colorectal cancer (41:17) Case: A woman in her early 40s with resected lower risk Stage III colon cancer requests ctDNA testing (45:47) Case: A man in his early 50s with Stage IIIB colon cancer wants to avoid adjuvant chemotherapy (50:39) Case: A man in his early 60s with Stage IV colon cancer receives a positive postoperative ctDNA assessment result (53:24) NCPD information and select publications
Featuring an interview with Dr Hanny Al-Samkari, including the following topics: Mechanism of action and toxicity of the monoclonal antibody ianalumab (0:00) Primary results from VAYHIT2, a randomized, double-blind Phase III trial of ianalumab with eltrombopag for patients with primary immune thrombocytopenia (ITP) after failure of first-line corticosteroid treatment (7:32) Mechanism of action and toxicity of the Bruton tyrosine kinase inhibitor rilzabrutinib (11:52) Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent or chronic ITP in the long-term extension period of the Phase III LUNA3 study (18:46) CME information and select publications
Featuring perspectives from Dr Hope S Rugo and Dr Sara M Tolaney, including the following topics: Introduction: Long-Term Outcomes with Antibody-Drug Conjugates (0:00) HER2-Positive Breast Cancer (8:02) HER2-Negative Breast Cancer (32:41) CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Antibody-Drug Conjugates for Breast Cancer | Faculty Presentation 2: Current and Emerging Role of TROP2-Directed ADCs — Sara M Tolaney, MD, MPH CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Antibody-Drug Conjugates for Breast Cancer | Faculty Presentation 1: Current and Emerging Role of HER2-Directed Antibody-Drug Conjugates (ADCs) — Hope S Rugo, MD CME information and select publications
Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics: Introduction: Rational Treatment Goals for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)? (0:00) Current Considerations in the Selection of First-Line and Maintenance Therapy — Dr Borghaei (8:13) Case: A woman in her early 60s newly diagnosed with ES-SCLC who receives first-line atezolizumab/EP and maintenance atezolizumab with delayed addition of lurbinectedin — Dr Borghaei (16:21) Case: A woman in her mid 60s with multiple comorbidities newly diagnosed with ES-SCLC who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin with discontinuation of lurbinectedin — Dr Borghaei (23:46) Clinician Survey Results (32:16) Case: A woman in her early 70s with multiple comorbidities and newly diagnosed ES-SCLC with TP53 and RB1 mutations who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin — Dr Chiang (41:39) Case: A man in his mid 70s with multiple comorbidities and a history of limited-stage SCLC managed with chemoradiation therapy who enrolls in the DeLLphi-312 trial upon disease recurrence — Dr Chiang (47:20) Promising Investigational Strategies — Dr Chiang (49:14) CME information and select publications
Featuring an interview with Dr Stacey A Cohen, Dr Arvind Dasari and Dr Christopher Lieu, including the following topics: Biological Principles Underlying Circulating Tumor DNA (ctDNA) Molecular Residual Disease (MRD) Testing in Colorectal Cancer (CRC) — Dr Cohen (0:00) Potential Utility of ctDNA Testing to Identify Patients with Localized CRC Who Might Benefit from Treatment De-escalation or Escalation — Dr Lieu (17:44) Role of ctDNA Analysis in the Management of Metastatic CRC – Dr Dasari (36:16) Clinical Investigator Survey Results (56:06) Case: A woman in her early 40s with mismatch repair-proficient/microsatellite-stable (MSS), low-risk Stage II colon cancer — Dr Lieu (1:23:05) Case: A woman in her early 70s with microsatellite instability-high Stage III colon cancer with a BRAF mutation — Dr Cohen (1:26:06) Case: A man in his mid 40s with metastatic CRC — Dr Dasari (1:31:57) Case: A man in his early 50s with low-risk Stage III colon cancer — Dr Lieu (1:37:54) Case: A man in his early 30s with MSS, high-risk Stage II CRC — Dr Cohen (1:50:17) Case: A woman in her early 50s with metastatic CRC — Dr Dasari (1:52:05) Case: A man in his early 60s with Stage IV colon cancer — Dr Lieu (1:56:05) CME information and select publications
Featuring an interview with Dr Terence Friedlander, including the following topics: Perioperative durvalumab with neoadjuvant chemotherapy: Health-related quality-of-life outcomes in the NIAGARA trial (0:00) Targeting HER2 in locally advanced or metastatic urothelial carcinoma (5:17) TROP2-targeted antibody-drug conjugates for locally advanced or metastatic urothelial carcinoma (18:19) CME information and select publications
Featuring perspectives from Dr Natalie S Callander and Dr Paul G Richardson, including the following topics: Introduction: Clinical Trials We LOVE to Discuss (0:00) Mechanism of Action of Cereblon E3 Ligase Modulators (CELMoDs) (8:42) Available Efficacy Data with CELMoDs in the Management of Relapsed/Refractory Multiple Myeloma (MM) (15:59) Extramedullary Disease (19:23) Spectrum and Management of CELMoD-Associated Adverse Events (30:12) Ongoing Phase II and III Trials Evaluating CELMoDs for MM (34:53) CME information and select publications
Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: Case: A man in his early 60s with urothelial bladder cancer (UBC) is found to have metastatic disease shortly after surgery (0:00) Case: A man in his late 70s experiences disease progression after first- and second-line treatment for metastatic disease (7:39) Case: A fit man in his early 70s presents with metastatic disease (15:22) CME information and select publications
Featuring perspectives from Dr Terence Friedlander and Dr Rana R McKay, including the following topics: Introduction (0:00) Up-Front Treatment of Ovarian Cancer (OC) (1:13) Management of Platinum-Resistant OC (11:49) Up-Front Management of Metastatic Endometrial Cancer (32:42) Management of HER2-Positive Gynecologic Cancers (45:11) Management of Cervical Cancer (53:10) CME information and select publications
Featuring an interview with Dr Sagar Lonial, including the following topics: Phase 3 randomized study evaluating teclistamab and daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib for patients with relapsed/refractory (R/R) multiple myeloma (MM) (0:00) Management of belantamab mafodotin-associated ocular events with dose modifications guided by standard assessments (3:15) Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone for transplant-ineligible patients with newly diagnosed MM (8:00) Other investigational strategies for R/R MM (12:55) CME information and select publications
Featuring an interview with Dr Marwan Fakih, including the following topics: Etiology and incidence of squamous cell carcinoma of the anal canal (SCAC) (0:00) Novel therapeutic strategies for the treatment of SCAC: Immunotherapy combinations and monitoring for recurrence with circulating tumor DNA assessment (4:37) Perspectives on the overall survival benefit observed with first-line retifanlimab and carboplatin/paclitaxel; potential for cure for patients with SCAC (8:22) Case: A woman in her mid 60s with recurrent unresectable metastatic SCAC receives retifanlimab with carboplatin/paclitaxel (16:56) Case: A woman in her mid 60s with recurrent unresectable metastatic SCAC receives single-agent immunotherapy (25:22) Case: A woman in her 60s with previously untreated metastatic SCAC receives chemotherapy and attains a complete response (29:21) Future directions for the treatment of SCAC (33:22) CME information and select publications
Featuring a slide presentation and related discussion from Dr Marwan Fakih, including the following topics: Overview of etiology, incidence and staging of squamous cell cancer of the anal canal (SCAC) (0:00) Systemic therapy approaches to the management of recurrent unresectable and metastatic SCAC (6:17) Available data with anti-PD-1 (pembrolizumab, nivolumab, retifanlimab) and anti-CTLA-4 (ipilimumab) agents in the management of unresectable metastatic SCAC previously treated with chemotherapy (12:59) Immunotherapy combined with chemotherapy for the front-line treatment of SCAC (20:48) Efficacy and safety of retifanlimab combined with carboplatin/paclitaxel as first-line treatment for SCAC in the Phase III POD1UM-303 trial (23:43) CME information and select publications
Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: EMBARK trial: Enzalutamide for biochemically recurrent prostate cancer (0:00) Final results from the Phase III PRESTO study: Combined androgen blockade for high-risk biochemically relapsed prostate cancer (4:05) Other novel treatment strategies for patients with metastatic prostate cancer (10:31) CME information and select publications
Featuring an interview with Dr Kathleen N Moore, including the following topics: Overview of the mechanism of action and pharmacology of antibody-drug conjugates (ADCs) (0:00) Comparing toxicities of conventional chemotherapy and ADCs (6:26) Potential of ADCs as maintenance therapy for ovarian cancer (11:35) Treatment based on platinum sensitivity and homologous recombination-deficiency status (15:10) Case: A woman in her mid 70s presenting with Stage IV ovarian cancer receives raludotatug deruxtecan (18:46) Case: A woman in her mid 60s with relapsed/refractory ovarian cancer receives mirvetuximab soravtansine (41:22) Case: A woman in her early 70s with relapsed/refractory ovarian cancer receives multiple ADCs in clinical trials (45:57) CME information and select publications
Download from Google Play
Download from App Store
United States
very informative, thanks 🙏
great podcast, very informative